66th ASH Annual Meeting: 908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care

Symposia: Outcomes Research: Myeloid Malignancies Oral and Poster Abstracts
Oral

Research, MDS, Adult, AML, Acute Myeloid Malignancies, Clinical Practice (Health Services and Quality), Epidemiology, Workforce, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), Pediatric, Supportive Care, Diseases, Patient-reported outcomes, Real-world evidence, Treatment Considerations, Young adult , Registries, Myeloid Malignancies, Study Population, Human, Transfusion, Measurable Residual Disease

Grand Hall C (Manchester Grand Hyatt San Diego)

Moderators:

Nandita Khera, MD, Mayo Clinic and Brittany Knick Ragon, MD, Levine Cancer Institute

Disclosures:

Ragon: Genentech: Consultancy, Other: Advisory Board ; Pfizer: Consultancy, Other: Advisory Board ; Astellas: Consultancy, Other: Advisory Board; Syndax: Consultancy, Other: Advisory Board.

9:30 AM

115

Incidence and Risk of Therapy-Related Myeloid Neoplasms in Solid Cancer: A Danish National Population-Based Matched Cohort Study

Tine Bichel Lauritsen, MD, PhD¹^*, Dennis Lund Hansen, MD, PhD²^*, Jan M Norgaard, MD, PhD, DMSc¹, Susanne Dalton, MD, DMSc, Prof^3,4^*, Kirsten Gronbaek, MD, PhD, PR^5,6, Tarec Christoffer El-Galaly, MD, DMSc, Prof^2,7,8 and Lene Sofie Granfeldt Østgård^2,9^*

¹Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
²Department of Hematology, Odense University Hospital, Odense, Denmark
³Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Næstved, Denmark
⁴Cancer Survivorship, Danish Cancer Institute, Danish Cancer Society Research Center, Copenhagen, Denmark
⁵Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark
⁶Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
⁷Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
⁸Department of Hematology, Aalborg Hospital, Aalborg, Denmark
⁹Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark

9:45 AM

116

Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

Daniel J. Zheng, MD¹, Gary Hettinger, MS²^*, Lusha Cao, PhD, MS³^*, Caitlin W. Elgarten, MD¹^*, Brian T. Fisher, DO, MPH, MSCE^2,4^*, Cody Gathers, MD, MSHP⁵^*, Yuan-Shung V. Huang, MS³^*, Jennifer Ko²^*, Kasey Leger, MD, MSc⁶, Yimei Li, PhD^1,2^*, Regina M. Myers, MD¹, Hari K. Narayan⁷^*, Jose Ortiz^1,2^*, Alix E. Seif, MD, MPH¹, Richard Aplenc^1,8 and Kelly D. Getz, PhD²

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
²Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
³Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA
⁴Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA
⁵Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA
⁶Division of Pediatric Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
⁷Department of Pediatrics, University of California San Diego, La Jolla, CA
⁸Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

10:00 AM

117

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Areej El-Jawahri, MD¹, Alison R Kavanaugh²^*, Joseph A Greer, PhD^2,3^*, Vicki Jackson, MD²^*, Jillian Gustin, MD⁴^*, Alice Mims, MD⁵, Albert Cook, MD⁶^*, Thomas W. LeBlanc, MD, MA, MS⁷, Amir T. Fathi, MD⁸, Gabriela S. Hobbs, MD⁹, Andrew M. Brunner, MD¹⁰ and Jennifer S Temel²^*

¹Massachusetts General Hospital, Allston, MA
²Massachusetts General Hospital, Boston, MA
³Harvard Medical School, Boston, MA
⁴Palliative Care, Ohio State Univeristy, Columbus, OH
⁵The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁶Palliative Care, The Ohio State University, Columbus, OH
⁷Duke Cancer Institute, Hillsborough, NC
⁸Center for Leukemia, Massachusetts General Hospital Cancer Center, Boston, MA
⁹Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA
¹⁰Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

10:15 AM

118

The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Maria Diez-Campelo, MD, PhD¹^*, Sophie Park, MD, PhD², Tracey Iraca³^*, Mrudula B. Glassberg⁴^*, Marc DeCongelio⁵^*, Alison Bulkley⁵^*, Abisola Olopoenia⁵^*, Jennifer Lord-Bessen⁶^*, Grace Skiles⁵^*, Katie Aguinaga⁵^*, Neelanzana Paudel⁵^*, Oliver Will⁵^*, Dimana Miteva⁷^*, Christina Hughes⁸^*, Ahmed Hnoosh⁹^* and Aylin Yucel⁸^*

¹Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain
²Grenoble Alpes University, Grenoble Alpes University Hospital, Hematology Department, Grenoble, France
³The Myelodysplastic Syndromes Foundation, Yardville, NJ
⁴Bristol Myers Squibb, Madison, NJ
⁵Oracle Life Sciences, Austin, TX
⁶Bristol Myers Squibb, Lawrenceville, NJ
⁷Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
⁸Bristol Myers Squibb, Princeton, NJ
⁹Bristol Myers Squibb, Uxbridge, United Kingdom

10:30 AM

119

Challenges in Leukemia Diagnosis and Treatment in Mexico: A Survey By the Alliance for Leukemias in Mexico on Resource Availability, Infrastructure, and Access to Advanced Therapies for Leukemia Patients

Roberta Demichelis, MD¹, Gilberto Israel Barranco Lampón, MD²^*, Carlos Madrigal-Iberri³^*, Marlén K Sánchez-Peña, MD⁴^*, Maripaz Márquez, PhD, MBA⁴^*, Akemi Ishikawa⁵^*, Zhere Derian Garcia-Trujillo, MSc⁶^* and Raúl Martinez Castro, MD⁷^*

¹Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
²Hematology Department, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City. Mexico., Mexico City, EM, Mexico
³Medical and Patient Affairs Department, Servier Mexico, Mexico City, Mexico
⁴Servier Mexico, Mexico City, Mexico
⁵Pan-International CREEK Study Project Lead/Hematology Medical Manager, AstraZeneca Mexicoakemi, Mexico, Mexico
⁶Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
⁷Hematology Department, Hospital de Especialidades Centro Medico Nacional Siglo XXI, IMSS, CDMX, EM, Mexico

10:45 AM

120

Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Justin CT Loke, MD PhD^1,2,3, Charlotte Gaskell, BSc MSc⁴^*, Emily Yafai, BSc²^*, Sonia Fox, BSc²^*, Catherine Thomas, PhD, BSc²^*, Louise Hopkins²^*, Rebecca Boucher²^*, Rebecca Collings²^*, Steve Knapper, MRCP, FRCPath, DM⁵^*, Anjum Khan⁶^*, Jane Nunnick¹^*, Katie Randall⁷^*, Jenny O'Nions⁸^*, Tom Rider⁹^*, Arpad Toth¹⁰^*, Mary Frances McMullin, MD, FRCPath, FRCP¹¹, Sally Moore¹²^*, Victoria Drew¹³^*, Farooq Ahmad Wandroo, MD, FRCPath, FRCP¹⁴^*, Pratap Neelakantan¹⁵^*, Pramila Krishnamurthy, MD¹⁶^*, Charles Craddock, FRCP, FRCPath^1,17, Sylvia Rofael¹⁸^*, Vinit Upsani¹⁸^*, David M Lowe^18,19^* and Simon J Stanworth, MA, FRCP (Paeds, UK), DPhil, FRCPath^20,21,22^*

¹Queen Elizabeth Hospital, Birmingham, United Kingdom
²University of Birmingham, Birmingham, United Kingdom
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Cancer Research UK Trials Unit, University of Birmingham, Birmingham, United Kingdom
⁵Cardiff University School of Medicine, Cardiff, United Kingdom
⁶St James Hospital, Leeds, United Kingdom
⁷Warwick Hospital, Warwick, United Kingdom
⁸Department of Haematology, University College London Hospital, London, United Kingdom
⁹Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom
¹⁰Clatterbridge Cancer Centre, Liverpool, United Kingdom
¹¹BHSCT, Belfast, United Kingdom
¹²University Hospitals Bristol and Weston, Bristol, United Kingdom
¹³Bradford Teaching Hospital, Bradford, United Kingdom
¹⁴Sandwell & West Birmingham Hospitals, NHS Trust, Birmingham, United Kingdom
¹⁵Royal Berkshire Hospital, Reading, United Kingdom
¹⁶Dept. of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom
¹⁷University of Warwick, Coventry, United Kingdom
¹⁸University College London, London, United Kingdom
¹⁹Royal Free Hospital, London, United Kingdom
²⁰Oxford University Hospitals, Oxford, United Kingdom
²¹NHS Blood and Transplant, Oxford, United Kingdom
²²Department of Haematology, Oxford University, Oxford, United Kingdom

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

908.O2.3 908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care